Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
Browsing: Movement disorders
After careful evaluation of the ‘Right to Try ‘Act, BrainStorm have announced that it will not make NurOwn® available under this legislation at this time.
Dopamine agonists and prodrugs taken to treat Parkinson’s disease may cause impulse control disorders in over half the patients they are prescribed to.
According to a large study, individuals with Type 2 diabetes may have an increased risk of being diagnosed with Parkinson’s disease later in life.
The National Institute for Health and Care Excellence (NICE) has recommended the use of four out of six disease-modifying therapies in relapsing–remitting multiple sclerosis.
An abstract to be presented by the American Academy of Neurology (CA, USA) reports patients suffering from hand tremors may find relief with a novel, non-invasive nerve stimulation treatment.
A recently published study has indicated that all degrees of concussion may increase the risk of developing Parkinson’s disease.
This research article from Neurodegenerative Disease Management investigates how age and disease duration affects Parkinson’s treatment outcome with levodopa-carbidopa intestinal gel.
We bring together Parkinson’s advances from across research and industry from the year so far.
In this week’s round-up, we cover the latest industry news from depression and Parkinson’s disease. Find out more about our selection of the highlights this week.